open access

Vol 85, No 4 (2017)
REVIEWS
Published online: 2017-08-28
Submitted: 2017-04-28
Accepted: 2017-08-10
Get Citation

Pulmonary hypertension in diffuse parenchymal lung diseases — is there any benefit of PAH-specific therapy?

Monika Szturmowicz, Aneta Kacprzak, Jan Kuś
DOI: 10.5603/ARM.2017.0036
·
Pubmed: 28871590
·
Adv Respir Med 2017;85(4):216-223.

open access

Vol 85, No 4 (2017)
REVIEWS
Published online: 2017-08-28
Submitted: 2017-04-28
Accepted: 2017-08-10

Abstract

Pulmonary hypertension (PH) is diagnosed in 40–50% of the patients with end-stage diffuse parenchymal lung diseases (DPLD), and it is associated with significant worsening of life expectancy. Latest ERS/ESC guidelines recommend best available treatment of DPLD, and long-term oxygen therapy in the patients with PaO2 less than 60 mm Hg. Pulmonary arterial hypertension (PAH)-targeted drugs are not recommended in PH-DPLD patients, due to the risk of increasing the ventilation-perfusion mismatch, and consequently worsening of hypoxaemia. Nevertheless, PAH-oriented treatment may be beneficial to selected groups of patients. The authors try to find the answer to several important questions: is there any benefit of PAH-specific therapy in PH-DPLD, who should be the candidate for PAH-specific therapy, what class of drugs is most promising, and what outcome measures should be employed?

Abstract

Pulmonary hypertension (PH) is diagnosed in 40–50% of the patients with end-stage diffuse parenchymal lung diseases (DPLD), and it is associated with significant worsening of life expectancy. Latest ERS/ESC guidelines recommend best available treatment of DPLD, and long-term oxygen therapy in the patients with PaO2 less than 60 mm Hg. Pulmonary arterial hypertension (PAH)-targeted drugs are not recommended in PH-DPLD patients, due to the risk of increasing the ventilation-perfusion mismatch, and consequently worsening of hypoxaemia. Nevertheless, PAH-oriented treatment may be beneficial to selected groups of patients. The authors try to find the answer to several important questions: is there any benefit of PAH-specific therapy in PH-DPLD, who should be the candidate for PAH-specific therapy, what class of drugs is most promising, and what outcome measures should be employed?

Get Citation

Keywords

pulmonary hypertension, diffuse parenchymal lung diseases, PAH-specific therapy

About this article
Title

Pulmonary hypertension in diffuse parenchymal lung diseases — is there any benefit of PAH-specific therapy?

Journal

Advances in Respiratory Medicine

Issue

Vol 85, No 4 (2017)

Pages

216-223

Published online

2017-08-28

DOI

10.5603/ARM.2017.0036

Pubmed

28871590

Bibliographic record

Adv Respir Med 2017;85(4):216-223.

Keywords

pulmonary hypertension
diffuse parenchymal lung diseases
PAH-specific therapy

Authors

Monika Szturmowicz
Aneta Kacprzak
Jan Kuś

References (55)
  1. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015; 46(4): 903–975.
  2. Seeger W, Adir Y, Barberà JA, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013; 62(25 Suppl): D109–D116.
  3. Nunes H, Humbert M, Capron F, et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax. 2006; 61(1): 68–74.
  4. Shorr AF, Helman DL, Davies DB, et al. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J. 2005; 25(5): 783–788.
  5. Shorr AF, Wainright JL, Cors CS, et al. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J. 2007; 30(4): 715–721.
  6. Modrykamien AM, Gudavalli R, McCarthy K, et al. Echocardiography, 6-minute walk distance, and distance-saturation product as predictors of pulmonary arterial hypertension in idiopathic pulmonary fibrosis. Respir Care. 2010; 55(5): 584–588.
  7. Hayes D, Higgins RS, Black SM, et al. Effect of pulmonary hypertension on survival in patients with idiopathic pulmonary fibrosis after lung transplantation: an analysis of the United Network of Organ Sharing registry. J Heart Lung Transplant. 2015; 34(3): 430–437.
  8. Baughman RP, Engel PJ, Taylor L, et al. Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest. 2010; 138(5): 1078–1085.
  9. Oliveira RKF, Pereira CAC, Ramos RP, et al. A haemodynamic study of pulmonary hypertension in chronic hypersensitivity pneumonitis. Eur Respir J. 2014; 44(2): 415–424.
  10. Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006; 129(3): 746–752.
  11. Tanabe N, Taniguchi H, Tsujino I. Multi-institutional retrospective cohort study of patients with severe pulmonary hypertension associated with respiratory disease. Respirology. 2015; 20(5): 605–812.
  12. Shlobin OA, Brown AW, Nathan SD. Pulmonary Hypertension in Diffuse Parenchymal Lung Diseases. Chest. 2017; 151(1): 204–214.
  13. Dunham-Snary KJ, Wu D, Sykes EA, et al. Hypoxic Pulmonary Vasoconstriction: From Molecular Mechanisms to Medicine. Chest. 2017; 151(1): 181–192.
  14. Awano N, Inomata M, Ikushima S, et al. Histological analysis of vasculopathy associated with pulmonary hypertension in combined pulmonary fibrosis and emphysema: comparison with idiopathic pulmonary fibrosis or emphysema alone. Histopathology. 2017; 70(6): 896–905.
  15. Ventetuolo CE, Kawut SM, Lederer DJ. Plasma endothelin-1 and vascular endothelial growth factor levels and their relationship to hemodynamics in idiopathic pulmonary fibrosis. Respiration. 2012; 84(4): 299–305.
  16. Polomis D, Runo JR, Meyer KC. Pulmonary hypertension in interstitial lung disease. Curr Opin Pulm Med. 2008; 14(5): 462–469.
  17. Nathan SD. Pulmonary hypertension in interstitial lung disease. Int J Clin Pract Suppl. 2008(160): 21–28.
  18. Fartoukh M, Humbert M, Capron F, et al. Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med. 2000; 161(1): 216–223.
  19. Dauriat G, Mal H, Thabut G, et al. Lung transplantation for pulmonary langerhans' cell histiocytosis: a multicenter analysis. Transplantation. 2006; 81(5): 746–750.
  20. Fulton BG, Ryerson CJ. Managing comorbidities in idiopathic pulmonary fibrosis. Int J Gen Med. 2015; 8: 309–318.
  21. Le Pavec J, Humbert M, Mouthon L, et al. Systemic sclerosis-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010; 18(12): 1285–1293.
  22. Dalleywater W, Powell HA, Fogarty AW, et al. Venous thromboembolism in people with idiopathic pulmonary fibrosis: a population-based study. Eur Respir J. 2014; 44(6): 1714–1715.
  23. Swigris JJ, Olson AL, Huie TJ, et al. Increased risk of pulmonary embolism among US decedents with sarcoidosis from 1988 to 2007. Chest. 2011; 140(5): 1261–1266.
  24. Vorselaars ADM, Snijder RJ, Grutters JC. Increased number of pulmonary embolisms in sarcoidosis patients. Chest. 2012; 141(3): 826–827.
  25. Takahashi K, Taniguchi H, Ando M, et al. Mean pulmonary arterial pressure as a prognostic indicator in connective tissue disease associated with interstitial lung disease: a retrospective cohort study. BMC Pulm Med. 2016; 16(1): 55.
  26. Brewis MJ, Church AC, Johnson MK, et al. Severe pulmonary hypertension in lung disease: phenotypes and response to treatment. Eur Respir J. 2015; 46(5): 1378–1389.
  27. Hoeper MM, Behr J, Held M, et al. Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias. PLoS One. 2015; 10(12): e0141911.
  28. Adegunsoye A, Strek ME. Therapeutic Approach to Adult Fibrotic Lung Diseases. Chest. 2016; 150(6): 1371–1386.
  29. Sanchez O, Sitbon O, Jaïs X, et al. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest. 2006; 130(1): 182–189.
  30. King TE, Bradford WZ, Castro-Bernardini S, et al. ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22): 2083–2092.
  31. Richeldi LR, du Bois RM, Raghu G. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22): 2071–2082.
  32. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 2016; 47(1): 243–253.
  33. Nathan SD, Behr J, Cottin V, et al. Idiopathic interstitial pneumonia-associated pulmonary hypertension: A target for therapy? Respir Med. 2017; 122 Suppl 1: S10–S13.
  34. Lehtonen ST, Veijola A, Karvonen H, et al. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. Respir Res. 2016; 17: 14.
  35. King TE, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008; 177(1): 75–81.
  36. King TE, Brown KK, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011; 184(1): 92–99.
  37. Raghu G, Million-Rousseau R, Morganti A, et al. MUSIC Study Group. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Respir J. 2013; 42(6): 1622–1632.
  38. Raghu G, Behr J, Brown KK, et al. ARTEMIS-IPF Investigators*. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013; 158(9): 641–649.
  39. Zisman DA, Schwarz M, Anstrom KJ, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010; 363(7): 620–628.
  40. Rhagu G, Rochwerg B, Zhang Y, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: treatment of idiopathic pulmonary fibrosis an update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015; 192(2): e3–e19.
  41. May A, Kane G, Yi E, et al. Dramatic and sustained responsiveness of pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension to vasodilator therapy. Respir Med Case Rep. 2015; 14: 13–15.
  42. Keir GJ, Walsh SLF, Gatzoulis MA, et al. Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies. Sarcoidosis Vasc Diffuse Lung Dis. 2014; 31(2): 82–90.
  43. Saggar R, Khanna D, Vaidya A, et al. Changes in right heart haemodynamics and echocardiographic function in an advanced phenotype of pulmonary hypertension and right heart dysfunction associated with pulmonary fibrosis. Thorax. 2014; 69(2): 123–129.
  44. Han MK, Bach DS, Hagan PG, et al. IPFnet Investigators. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest. 2013; 143(6): 1699–1708.
  45. Zimmermann GS, von Wulffen W, Huppmann P, et al. Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors. Respirology. 2014; 19(5): 700–706.
  46. Baughman RP, Culver DA, Cordova FC, et al. Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial. Chest. 2014; 145(4): 810–817.
  47. Corte TJ, Keir GJ, Dimopoulos K, et al. BPHIT Study Group. Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2014; 190(2): 208–217.
  48. https://clinicaltrials.gov/ct2/show/NCT02138825.
  49. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2009; 179(2): 151–157.
  50. Le Pavec J, Girgis RE, Lechtzin N. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. Arthrit Rheum. 2011; 63(8): 2456–2464.
  51. Launay D, Sitbon O, Hachulla E, et al. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Ann Rheum Dis. 2013; 72(12): 1940–1946.
  52. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002; 360(9337): 895–900.
  53. Milara J, Escrivá J, Ortiz JL, et al. Vascular effects of sildenafil in patients with pulmonary fibrosis and pulmonary hypertension: an ex vivo/in vitro study. Eur Respir J. 2016; 47(6): 1737–1749.
  54. Hoeper MM, Halank M, Wilkens H, et al. Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial. Eur Respir J. 2013; 41(4): 853–860.
  55. Bonham CA, Oldham JM, Gomberg-Maitland M, et al. Prostacyclin and oral vasodilator therapy in sarcoidosis-associated pulmonary hypertension: a retrospective case series. Chest. 2015; 148(4): 1055–1062.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl